Sugi Predict

Sugi Predict / Compounds / SCHEMBL3595465

SCHEMBL3595465

SCHEMBL3595465

Clc1cc(N2CCOCC2)nc(-c2cccc3[nH]ccc23)n1

nearest known ligand 0.66

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 15/20 0.66
▸ PIK3CA P42336 9/20 0.66
▸ MTOR P42345 6/20 0.66
▸ PRKDC P78527 1/20 0.66
▸ PIK3CD O00329 4/20 0.54
▸ PIK3CB P42338 3/20 0.52
▸ PIK3CG P48736 3/20 0.52
▸ ATRIP Q8WXE1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29397370 1.00 ATR (0.66) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL19147383 0.86 ATR (0.70) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL3591720 0.85 ATR (0.69) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL21263177 0.84 ATR (0.75) ATRPIK3CAMTORPRKDCATRIP
SCHEMBL21263052 0.84 ATR (0.75) ATRPIK3CAMTORPRKDCATRIP
SCHEMBL19146366 0.84 ATR (0.77) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL1311642 0.82 ATR (0.60) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL3603778 0.81 ATR (0.73) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL1309409 0.81 PIK3CA (0.70) ATRPIK3CAMTORPRKDCPIK3CD
SCHEMBL1029005 0.80 ATR (0.62) ATRPIK3CAMTORPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-20 — — US disclosed
CN-110204544-B 2- (morpholin-4-yl) -1, 7-naphthyridine 拜耳制药股份公司 2022-04-12 — — CN disclosed
CN-110256427-B 2- (morpholin-4-yl) -1, 7-naphthyridine 拜耳制药股份公司 2022-02-22 — — CN disclosed
CN-108699057-B 5-substituted 2- (morpholin-4-yl) -1, 7-naphthyridines 拜耳医药股份公司 2021-11-09 — — CN disclosed
EP-3395818-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2021-09-22 — — EP disclosed
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-12-10 — — US disclosed
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-09-15 — — US disclosed
US-10729680-B2 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-08-04 — — US disclosed
EP-3402795-B1 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2019-10-30 — — EP disclosed
US-20190142812-A1 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-05-16 — — US disclosed
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-03 — — US disclosed
WO-2017121684-A1 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-07-20 — — WO disclosed
EP-3177619-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2017-06-14 — — EP disclosed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 — — US disclosed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 — — US disclosed
WO-2016020320-A1 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-11 — — WO disclosed
US-20100256143-A1 PHARMACEUTICAL COMPOUNDS BAKER STEWART JAMES 2010-10-07 — — US disclosed
US-20100130496-A1 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-05-27 — — US disclosed
EP-2146981-A1 PHARMACEUTICAL COMPOUNDS F. Hoffmann-Roche AG (CH) 2010-01-27 — — EP disclosed
WO-2008125833-A1 PHARMACEUTICAL COMPOUNDS PIRAMED LIMITED (GB) 2008-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10729680-B2 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines CCND2, BRCA1, CCNI ATR 3042/4885PIK3CA 963/4885MTOR 1927/4885
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS ATR 3508/4885PIK3CA 1050/4885MTOR 2033/4885
US-20100256143-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PIK3CD, JAK2 ATR 957/4885PIK3CA 1/4885MTOR 14/4885
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885PIK3CA 1050/4885MTOR 2033/4885
US-20100130496-A1 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE PIK3CA, PIP5K1B, PIK3CD ATR 453/4885PIK3CA 1/4885MTOR 30/4885
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885PIK3CA 1050/4885MTOR 2033/4885
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885PIK3CA 1050/4885MTOR 2033/4885
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS ATR 3508/4885PIK3CA 1050/4885MTOR 2033/4885
US-20190142812-A1 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES CCND2, BRCA1, CCNI ATR 3042/4885PIK3CA 963/4885MTOR 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.